(Q39466827)

12 September 2017

1 reference

title

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders (English)

1 reference

12 September 2017

1 reference

A Fitton

1

1 reference

12 September 2017

L Wiseman

series ordinal

2

1 reference

12 September 2017

language of work or name

1 reference

1 March 1996

1 reference

12 September 2017

1 reference

12 September 2017

volume

51

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

460-482

1 reference

The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog

12 September 2017

cites work

1 reference

12 December 2020

A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis : a multicentre trial

1 reference

12 December 2020

Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.

1 reference

12 December 2020

Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer

1 reference

12 December 2020

Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats

1 reference

12 December 2020

Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels.

1 reference

12 December 2020

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

1 reference

12 December 2020

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole

1 reference

12 December 2020

Pantoprazole does not interact with the pharmacokinetics of carbamazepine

1 reference

12 December 2020

Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease

1 reference

12 December 2020

Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors

1 reference

12 December 2020

Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles

1 reference

12 December 2020

A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group

1 reference

12 December 2020

Omeprazole drug interaction studies

1 reference

12 December 2020

Pharmacokinetics--a relevant factor for the choice of a drug?

1 reference

12 December 2020

Lack of pantoprazole drug interactions in man.

1 reference

12 December 2020

Is there any acid peptic disease that is refractory to proton pump inhibitors?

1 reference

12 December 2020

Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study

1 reference

12 December 2020

Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability

1 reference

12 December 2020

In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs

1 reference

12 December 2020

Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders

1 reference

12 December 2020

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

1 reference

12 December 2020

Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy

1 reference

12 December 2020

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction

1 reference

12 December 2020

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

12 December 2020

Drug interactions involving cimetidine--mechanisms, documentation, implications

1 reference

12 December 2020

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]

1 reference

12 December 2020

In vivo and in vitro studies of the site of inhibitory action of omeprazole on adrenocortical steroidogenesis

1 reference

12 December 2020

Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease

1 reference

12 December 2020

Continuing development of acid pump inhibitors: site of action of pantoprazole.

1 reference

12 December 2020

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

1 reference

12 December 2020

Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.

1 reference

12 December 2020

High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up

1 reference

12 December 2020

By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor

1 reference

12 December 2020

Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori

1 reference

12 December 2020

One-week low-dose triple therapy: new standards for Helicobacter pylori treatment

1 reference

12 December 2020

Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.

1 reference

12 December 2020

Two systems for the automated analysis of drugs in biological fluids using high-performance liquid chromatography

1 reference

12 December 2020

Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.

1 reference

12 December 2020

Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

1 reference

12 December 2020

Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man.

1 reference

12 December 2020

The site of acid secretion in the mammalian parietal cell

1 reference

12 December 2020

Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat

1 reference

12 December 2020

Ketoconazole Blocks Adrenal Steroid Synthesis

1 reference

12 December 2020

The H+,K+-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole

1 reference

12 December 2020

Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients

1 reference

12 December 2020

The interaction of proton pump inhibitors with cytochromes P450.

1 reference

12 December 2020

How should we decide on the best regimen for eradicating Helicobacter pylori?

1 reference

12 December 2020

Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study

1 reference

12 December 2020

Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers

1 reference

12 December 2020

Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

1 reference

12 December 2020

BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.

1 reference

12 December 2020

(H+, K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate

1 reference

12 December 2020

Antibacterial activity of pantoprazole and omeprazole againstHelicobacter pylori

1 reference

12 December 2020

The site of action of pantoprazole in the gastric H+/K(+)-ATPase

1 reference

12 December 2020

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori

1 reference

12 December 2020

The pharmacology of the gastric acid pump: the H+,K+ ATPase

1 reference

12 December 2020

Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer

1 reference

12 December 2020

The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation

1 reference

12 December 2020

[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection]

1 reference

12 December 2020

Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study

1 reference

12 December 2020

Effects of pantoprazole on endocrine function in healthy male volunteers

1 reference

12 December 2020

Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment

1 reference

12 December 2020

D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy

1 reference

12 December 2020

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man

1 reference

12 December 2020

Stereoselective interaction of omeprazole with warfarin in healthy men

1 reference

12 December 2020

Effect of omeprazole and cimetidine on plasma diazepam levels.

1 reference

12 December 2020

Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl)benzimidazole products

1 reference

12 December 2020

Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion

1 reference

12 December 2020

Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up

1 reference

12 December 2020

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs

1 reference

12 December 2020

No influence of pantoprazole on the pharmacokinetics of phenytoin

1 reference

12 December 2020

1 reference

12 December 2020

NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease

1 reference

12 December 2020

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders

1 reference

12 December 2020

Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

1 reference

12 December 2020

Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration

1 reference

12 December 2020

Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.

1 reference

12 December 2020

10.2165/00003495-199651030-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

1019374600

0 references

1 reference